Exclusive-Air India in talks for major new narrow-body jet order, sources say
By Tim Hepher, Aditi Shah and Rajesh Kumar Singh
NEW DELHI (Reuters) -Tata Group's Air India is in talks with Airbus and Boeing for a major new aircraft order including some 200 extra single-aisle planes, topping up a mammoth deal in 2023 as the former state carrier pursues a multi-billion-dollar revamp, industry sources said.
The order discussions, which two of the sources said could involve hundreds of airplanes in total spread across various sizes, expand on previously reported discussions for a further batch of large wide-body aircraft, they told Reuters.
In those talks, Boeing is edging forward as the front-runner to sell more of its 777X jets, two of the sources said.
Air India, Boeing and Airbus all declined to comment.
Word of a potential new blockbuster order from India's flag carrier emerged as global airline bosses gathered in the world's fastest-growing aviation market for a Delhi industry summit to be addressed by Indian Prime Minister Narendra Modi on Monday.
Air India placed a then-record order for 470 planes from both suppliers in 2023 and another 100 Airbus jets last year.
The back-to-back plane orders come at a time when aircraft manufacturers are scrambling with supply chain issues leading to severe delays in aircraft delivery and a looming jet shortage.
Getting new planes is crucial for Air India, which has suffered from years of under-investment under government ownership and is now undertaking an ambitious modernisation plan to recapture market share lost to global rivals.
One of the sources said the potential new narrow-body jet order provisionally involved 200 aircraft, while two others estimated the volume in the hundreds.
The timing of any deal was not immediately clear and one source said pricing could be a stumbling block as Air India seeks to emulate deals by India's largest carrier IndiGo, which announced new partnerships and a top-up Airbus order on Sunday.
Multi-billion-dollar aircraft orders typically take months of closely held talks to negotiate, with any Boeing and Airbus components usually being announced separately.
India's aviation market is expanding at some 7% a year, according to Airbus forecasts. But analysts say its growth remains hampered by weak infrastructure, especially as it looks to connect hinterlands to bigger cities.
On the eve of the airline meeting in the Indian capital, the International Air Transport Association of 300 global carriers said the country's airlines were poised to demonstrate continued rapid growth, clouded by expensive fuel costs and high taxes.
(Additional reporting by Shivansh Tiwary, Nandan Mandayam; Editing by Elaine Hardcastle and Sophie Walker)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Big Idea Ventures and Mars Petcare Launch 2025 Global Pet Food Innovation Program in Collaboration with AAK, Bühler, and Givaudan
Building on the success of last year's program, the second round aims to find the next cohort of trailblazers who can deliver innovation in the sustainable pet food space. Startups from around the world are invited to apply, with selected participants to showcase their solutions at the Asia-Pacific Agri-Food Innovation Summit. The program continues to unite leading food and pet care experts to accelerate sustainable pet food innovation. New York, NY , June 03, 2025 (GLOBE NEWSWIRE) -- Following the success of last year's program, Big Idea Ventures and Mars Petcare will launch the second round of the Next Generation Pet Food Program, in collaboration with AAK, Bühler, and Givaudan. This initiative aims to accelerate sustainable innovation in the pet food sector by supporting startups with novel ingredients, sustainable fats and proteins, and advanced processing technologies. Mars is exploring alternative ingredients in its pet food products to create more sustainable, future-ready nutrition. As consumer preference evolves Mars is working to give pet parents the opportunity to make more environmentally conscious choices, while taking steps to reduce its own carbon footprint. This year, Givaudan, a global leader in taste and wellbeing, joins AAK and Bühler as a collaborator, offering expertise in ingredient innovation and product development for humans and pets. Andrew D. Ive, Founder and Managing General Partner of Big Idea Ventures, stated:"Working with Mars last year was fantastic! We want to take the learnings and implement them on a big scale as we continue to search for and develop sustainable solutions for the pet food ecosystem. Last year, the teams from Mars Petcare, Bühler, and AAK offered invaluable insights to our startups. Now, by integrating Givaudan into the mix, we will further enhance the resources available to the startups we choose.' Paul Gardner, Commercial VP, Mars Pet Nutrition added: 'We must invest in innovation to help us source the best ingredients and build a future where the planet stays healthy, and where people and their pets are thriving. We're excited to be launching the second round of this program harnessing the creativity of startups, alongside partners that share our vision' 'We were thrilled at the enthusiastic response we got from last's program. It is a testament that innovative startups are the driving force behind the future of sustainable pet nutrition. The program offers a unique opportunity for visionary entrepreneurs to collaborate with leading industry experts, access state-of-the-art technology, and accelerate their impact on the global petfood market. I encourage all startups with bold ideas and a passion for transformation to apply and help us shape a healthier, more sustainable future for pets and planet alike,' said Dr. Ian Roberts, CTO at Bühler Group. Niall Sands, President Commercial Innovation and Development, AAK, shared that the company is excited to support pet food innovators to bring nutrition and health-promoting functionality to our beloved pets. They look forward to exploring how innovation in this space is helping pet parents support and care for our 4-legged family members. Fabio Campanile, Global Head of Science & Technology, Givaudan Taste & Wellbeing, noted, 'Givaudan is excited to be part of this program as it presents a unique opportunity to collaborate with innovative startups and partners, paving the way for a more sustainable and enriching world for pets. We look forward to building on our current capabilities in the pet food space as well as exploring new technologies.' Companies selected for the program will benefit from expert guidance, potential commercial partnerships, and the opportunity to showcase their solutions on a global stage at Asia-Pacific Agri-Food Innovation Summit in Singapore from November 4–6, 2025. Winners of the 2024 Global Pet Food Innovation Program include BiomeMega, Anomaly Bio, KIDEMIS, String Bio Private Limited, MiAlgae, who have been under the mentorship of Big Venture Idea, Mars, AAK and Bühler. The startups have gained insights from top pet food experts and collaborated with leading CPG, ingredient, and technology companies to further develop their concepts with the potential to develop future long-term collaborations. The program is open to startups from around the world, with a strong preference for scalable solutions that can demonstrate real-world impact and sustainability. While APAC-based startups are preferred, companies from all geographies are encouraged to apply. For more information, visit Interested startups are encouraged to apply here as early as possible and will be able to do so until July 16. Media contacts: Bühler: Dalen Jacomino Panto, Media Relations Manager Bühler AG, 9240 Uzwil, Switzerland Phone: +41 71 955 37 57 Mobile: +41 79 900 53 88 E-mail: Katja Hartmann, Media Relations ManagerBühler AG, 9240 Uzwil, Schweiz Mobile: +41 79 483 68 07 E-mail: Jeff Peppet, Content and Communications Director, T&W +1 513 293 3740AAK: Carl Ahlgren Head of Investor Relations and Corporate Communication IR, Communications and Brand Malmo, Sweden +46706810734 Alex Lloyd, Global R&D Communications Senior Manager Email: Idea Ventures: 259 Nassau St Ste 2, #1292 Princeton, NJ 08542 Shruti Salkar Email: news@ the Partners Big Idea Ventures Big Idea Ventures is the leading investor in food and agri technology globally. As one of the most active investors in the food-tech, agri-tech, and materials science sectors, we focus on identifying and investing in the most innovative and sustainable technology companies around the world. We collaborate with universities for tech transfer and by combining capital, knowledge, and partnerships, we drive economic growth and help to create food ecosystems. Our collaborations with leading corporations and governments aim to support entrepreneurs, scientists, and engineers in solving some of the world's biggest challenges. Big Idea Ventures has teams in New York, Paris and Asia and has invested in more than 120 companies across 30 countries. Incorporated Mars, Incorporated is driven by the belief that the world we want tomorrow starts with how we do business today. As a $50bn+ family-owned business, our diverse and expanding portfolio of leading pet care products and veterinary services support pets all around the world and our quality snacking and food products delight millions of people every day. We produce some of the world's best-loved brands including ROYAL CANIN®, PEDIGREE®, WHISKAS®, CESAR®, DOVE®, EXTRA®, M&M'S®, SNICKERS® and BEN'S ORIGINAL™. Our international networks of pet hospitals, including BANFIELD™, BLUEPEARL™, VCA™ and ANICURA™ span preventive, general, specialty, and emergency veterinary care, and our global veterinary diagnostics business ANTECH® offers breakthrough capabilities in pet diagnostics. The Mars Five Principles — Quality, Responsibility, Mutuality, Efficiency and Freedom — inspire our 150,000 Associates to act every day to help create a better world for people, pets and the planet. Everything AAK does is about Making Better Happen™. We specialize in plant-based oils and fats, the value-adding ingredients in many products people love to consume. We make these products better tasting, healthier, and more sustainable. At the heart of AAK's offer is Customer Co-Development, combining our desire to understand what Making Better Happen™ means for each customer, with the unique flexibility of our production assets, and deep knowledge of products and industries, including Chocolate & Confectionery, Bakery, Dairy, Plant-based Foods, Special Nutrition, Foodservice, and Personal Care. Our 4,100 employees support our close collaboration with customers through 25 regional sales offices, 16 dedicated Customer Innovation Centers, and with the support of more than 20 production facilities. Listed on Nasdaq Stockholm and headquartered in Malmö, Sweden, AAK has been Making Better Happen™ for more than 150 years. Bühler is driven by its purpose of creating innovations for a better world, balancing the needs of economy, humanity, and nature in all its decision-making processes. Billions of people come into contact with Bühler technologies as they cover their basic needs for food and mobility every day. Two billion people each day enjoy foods produced on Bühler equipment; and one billion people travel in vehicles manufactured using parts produced with Bühler solutions. Countless people wear eyeglasses, use smartphones, and read newspapers and magazines – all of which depend on Bühler process technologies and solutions. Having this global relevance, Bühler is in a unique position to turn today's global challenges into sustainable business. As a technology partner for the food, feed, and mobility industries, Bühler has committed to having solutions ready to multiply by 2025 that reduce energy, waste, and water by 50% in the value chains of its customers. It also proactively collaborates with suppliers to reduce climate impacts throughout the value chain. In its own operations, Bühler has developed a pathway to achieve a 60% reduction of greenhouse gas emissions by 2030 (Greenhouse Gas Protocol Scopes 1 & 2, against a 2019 baseline). Bühler spends up to 5% of turnover on research and development annually to improve both the commercial and sustainability performance of its solutions, products, and services. In 2023, some 12,500 employees generated a turnover of CHF 3.0 billion. As a Swiss family-owned company with a history spanning 164 years, Bühler is active in 140 countries around the world and operates a global network of 105 service stations, 30 manufacturing sites, and Application & Training Centers in 25 locations. Givaudan is a global leader in Fragrance & Beauty and Taste & Wellbeing. We celebrate the beauty of human experience by creating happier, healthier lives with love for nature. Together with our customers, we deliver food experiences, craft inspired fragrances, and develop beauty and wellbeing solutions that make people look and feel good. From your favourite drink to your daily meal, from prestige perfumes to laundry care, our products help people live happier and healthier lives, and we create them in a way that respects natural resources and the environment.
Yahoo
an hour ago
- Yahoo
Asia-Pacific NIPT Market to Hit USD 4.57 Billion by 2033: Growth Driven by Technological Advancements and Healthcare Reforms
Developed countries like Japan and South Korea have integrated NIPT into healthcare systems, while emerging markets like China and India are witnessing rapid adoption due to improved healthcare access and insurance reforms Asia-Pacific Non-Invasive Prenatal Testing Market Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Non-Invasive Prenatal Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to offering. The Asia-Pacific Non-Invasive Prenatal Testing Market is expected to reach US$ 4.57 billion by 2033 from US$ 1.33 billion in 2024, with a CAGR of 14.64% from 2025 to 2033. The market is expanding due to factors such the demand for precise and prompt prenatal diagnoses, the usage of advanced genetic technology, and the aging of mothers. The introduction of healthcare reforms in several Asia-Pacific countries and the extension of insurance coverage for prenatal care are further encouraging the usage of NIPT. The non-invasive prenatal testing (NIPT) market in Asia-Pacific is expanding quickly due to factors including growing mother age, improved genetic testing technology, and growing awareness of prenatal care. Asia-Pacific, one of the most populated and varied regions, is home to nations with a range of socioeconomic backgrounds and healthcare infrastructure levels. This discrepancy has made NIPT adoption both difficult and possible. NIPT is becoming a common component of prenatal treatment in nations with highly developed healthcare systems, such as South Korea, Singapore, and Japan, especially for high-risk pregnancies. Meanwhile, as healthcare access improves and more women look for safer, more accurate screening alternatives, the demand for NIPT is rising quickly in emerging areas like China, India, and Southeast Asia. The Asia-Pacific region's more developed nations have robust healthcare systems, supportive governments, and high public awareness, all of which contribute to the NIPT industry. Due to its integration into national screening programs for high-risk pregnancies, NIPT is widely available and reasonably priced. Effective use of NIPT to identify chromosomal abnormalities and guide pregnancy treatment is ensured by the availability of qualified genetic counselors and established medical procedures. Technological advancements and the accessibility of sophisticated screening techniques in these areas further propel market growth. Less developed regions of the Asia-Pacific still face difficulties, nevertheless. NIPT is still a luxury service that is expensive and scarce in nations with inadequate healthcare resources or where healthcare systems are still developing. Barriers to broader acceptability also include ethical issues about genetic screening and cultural views on prenatal testing. Therefore, it is necessary to overcome both cultural opposition and infrastructure constraints in order to expand the NIPT market in these nations. For NIPT to become more widely available and reasonably priced throughout the Asia-Pacific region, it will be essential to maintain investments in healthcare infrastructure, public awareness initiatives, and legislative backing. The high cost of these tests, leading to relatively low affordability in many developing countries, will limit their adoption. According to an article published by Future Medicine, the average cost of non-invasive prenatal testing in India is around USD 350 to USD 400. According to an article published by the Australian Broadcasting Corporation in May 2022, an NIPT costs around USD 500 and is a high out-of-pocket cost during pregnancy, pressuring families to terminate their pregnancies after the first positive test for Down's syndrome. This has limited their uptake in emerging countries. Growth Drivers for the Asia-Pacific Non-Invasive Prenatal Testing Market Advancements in Genetic Testing Technology Non-invasive prenatal testing (NIPT) is now much more accurate, quick, and affordable because to developments in genetic testing technology, especially next-generation sequencing (NGS) and bioinformatics. Rapid fetal DNA analysis from maternal blood samples is made possible by NGS, which improves the test's sensitivity and specificity, particularly for identifying chromosomal disorders like Down syndrome. Advances in bioinformatics enable the rapid processing of enormous volumes of genetic data, cutting down on testing expenses and time. Because of these technical developments, NIPT is now more widely available to pregnant mothers in both developed and growing Asia-Pacific economies. As a result, NIPT is becoming more widely used worldwide, providing safer and more precise prenatal screening alternatives. Government Support and National Screening Programs The expansion of non-invasive prenatal testing (NIPT) throughout Asia is mostly due to government assistance and national screening initiatives. Because NIPT has been included into national healthcare systems in nations like Singapore and Japan, expecting moms may easily obtain and use it. These countries lower the dangers associated with intrusive testing techniques while also improving early diagnosis of chromosomal abnormalities by providing NIPT as part of standard prenatal care. Furthermore, NIPT's wider acceptability is facilitated by public health campaigns that inform patients of its advantages. Government support makes NIPT a dependable and crucial instrument in prenatal care throughout the area by helping to standardize its usage. Expansion of Private Healthcare A wider population now has far better access to non-invasive prenatal testing (NIPT) because to the growth of private healthcare providers in nations like Thailand and India. Private healthcare institutions provide advanced testing alternatives, such as NIPT, that might not be available in public systems because to the growing need for quicker and more thorough care. This expansion is especially helpful for pregnant moms who want more individualized care or faster outcomes. A greater variety of patients may now get sophisticated prenatal screening as private healthcare providers increase NIPT's accessibility and price, therefore closing the wealth gap between high- and middle-income groups. Additionally, this growth promotes healthy competition, which raises the standard and effectiveness of prenatal care. Challenges in the Asia-Pacific Non-Invasive Prenatal Testing Market Inconsistent Regulation and Standardization The Asia-Pacific non-invasive prenatal testing (NIPT) industry has major obstacles due to inconsistent legislation and standards. Different nations have different NIPT regulatory frameworks, which causes variations in certification, quality assurance, and testing procedures. The accuracy and dependability of results may be impacted in some areas by inadequate laboratory oversight or unclear test process recommendations. The safety and efficacy of the tests may be questioned as different nations may provide NIPT services of varying quality in the absence of uniform rules. This discrepancy can erode patient faith in NIPT, particularly in nations with laxer regulations, which would prevent the technique from being widely adopted and trusted. Infrastructure Challenges in Emerging Markets Non-invasive prenatal testing (NIPT) may not be widely available in developing nations with underdeveloped healthcare systems, especially in rural or isolated places. Modern medical facilities and specialist labs, which are usually concentrated in metropolitan areas, are frequently necessary for the availability of NIPT. Therefore, access to this advanced prenatal screening may be severely hampered for pregnant moms in impoverished or rural areas. Due to limited availability to NIPT, a sizable portion of the population is unable to take advantage of early genetic abnormality diagnosis. Investment in medical facilities, better diagnostic service distribution, and efforts to increase access to NIPT in less accessible areas are all necessary to address these infrastructural issues and guarantee more equal access to healthcare. Key Attributes Report Attribute Details No. of Pages 200 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $1.4 Billion Forecasted Market Value (USD) by 2033 $4.58 Billion Compound Annual Growth Rate 14% Regions Covered Asia-Pacific Key Topics Covered1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Asia-Pacific Non-Invasive Prenatal Testing Market6. Market Share Analysis6.1 Component6.2 Application6.3 End User7. Asia-Pacific - Countries Non-Invasive Prenatal Testing Market7.1 China7.2 Japan7.3 India7.4 Australia7.5 South Korea7.6 Thailand7.7 Malaysia7.8 Indonesia7.9 New Zealand8. Component8.1 Instruments8.2 Kits and Reagents8.3 Services9. Application9.1 Down Syndrome (trisomy 21)9.2 Edwards Syndrome (trisomy 18)9.3 Patau Syndrome (trisomy 13)9.4 Turner Syndrome9.5 Other Applications10. End User10.1 Hospitals10.2 Diagnostic Labs11. Porter's Five Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis13.1 Eurofins Scientific13.1.1 Overview13.1.2 Key Persons13.1.3 Recent Development & Strategies13.1.4 Financial Insight13.2 F. Hoffmann-La Roche Ltd.13.3 Invitae Corporation13.4 Illumina Inc.13.5 Natera Inc.13.6 Centogene N.V.13.7 Qiagen For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Non-Invasive Prenatal Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
an hour ago
- Yahoo
Alaska Airlines CEO expects full-year profit despite pricing struggles
By Rajesh Kumar Singh NEW DELHI (Reuters) -Alaska Airlines CEO Ben Minicucci said the company's pricing power has not recovered yet even as its bookings have stabilised following economic uncertainty that led to volatility in the first quarter. Still, Minicucci said the company expects to report a profit this year. In the current quarter, the Seattle-based carrier's earnings are shaping up along expected lines, he told Reuters on the sidelines of an IATA airline summit in New Delhi. Like most U.S. airlines, Alaska pulled its full-year financial forecast in April as President Donald Trump's trade war created the biggest uncertainty for the industry since the COVID-19 pandemic. With little clarity on how consumers would behave in the face of a potentially worsening economy, airlines said it was difficult to accurately forecast their business. Soft travel demand, meanwhile, has dampened U.S. airfares, which declined at their fastest pace in 16 months in April from a year ago, government data shows. "We're filling airplanes, just not at the yields we'd like," Minicucci said. Alaska has forecast an adjusted profit of $1.15 per share to $1.65 per share in the quarter ending June. The company's performance, thus far, is "solidly" in the forecast range, he said. The pullback in U.S. travel demand has been the sharpest among price-conscious consumers. Demand for high-end travel remains the "bright spot," Minicucci said. Alaska, which completed its acquisition of Hawaiian Airlines last year, is looking to drive up the share of premium travel in its revenue. The carrier will launch its first-ever transatlantic service next year, with a non-stop flight between Seattle and Rome. It is also adding more upscale seats on its aircraft. Premium cabins are estimated to account for 29% of its seats over the next three years, up from 25% at present, he said. The company, however, is having to deal with seat supply chain problems. Minicucci said seat manufacturers will need to expand production to keep up with strong demand. "They're oversubscribed right now," he said. IMPROVEMENTS AT BOEING Minicucci said he is encouraged by safety and quality improvements at planemaker Boeing. Alaska had to ground its fleet of MAX 9 aircraft last year after a door plug missing key bolts blew off one of the carrier's new jets at 16,000 feet. While the planemaker still has a lot of work ahead of it, he said it continues to make improvements "quarter over quarter." Boeing CEO Kelly Ortberg recently told trade publication Aviation Week that the company aimed to secure certification for the smallest and largest of its best-selling 737 MAX aircraft - the MAX 7 and MAX 10 - from the U.S. Federal Aviation Administration by the end of this year. The MAX 7 and MAX 10 have been delayed in part due to concerns with the engine de-icing system. Alaska is one of the airlines waiting for the MAX 10. Minicucci said the jet is not part of the carrier's plans until 2027. "We don't want to put pressure on Boeing," he said. "We want them to follow their own certification process."
